Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bezlotoxumab.

Stuart Johnson1,2, Dale N Gerding1

  • 1Hines Veterans Affairs Hospital, Hines, Illinois.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|July 19, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular epidemiology and clinical differentiation between <i>Clostridioides difficile</i> infection and colonization across three chicago medical centers.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

<i>Clostridioides difficile</i> Infection: Harmonizing Patient Care.

Gastro hep advances·2026
Same author

Clostridioides difficile colonization of Twin Patients Recovering From Infant Botulism.

Anaerobe·2026
Same author

<i>Clostridioides difficile</i> clinical diagnostic test methods and results are associated with recovery of <i>C. difficile</i> by stool culture.

Microbiology spectrum·2026
Same author

Towards functional food development: impact of extrusion cooking on phenolic compounds and antinutrients in sorghum and millets.

Critical reviews in food science and nutrition·2025
Same author

<i>Clostridioides difficile</i> in Peripartum Women: Review of Outcomes and Treatment.

Antibiotics (Basel, Switzerland)·2025
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Bezlotoxumab, a monoclonal antibody targeting Clostridium difficile toxin B, effectively reduced recurrent CDI in high-risk adults. While generally safe, caution is advised for patients with heart failure.

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Clostridium difficile infection (CDI) poses a significant health challenge, often recurring despite standard treatments.
  • CDI pathogenesis involves toxins A and B; therapeutic strategies target these toxins.
  • Monoclonal antibodies offer a targeted approach to neutralize C. difficile toxins.

Purpose of the Study:

  • To evaluate the efficacy and safety of bezlotoxumab, a fully human monoclonal antibody against C. difficile toxin B, as adjunctive therapy for preventing recurrent CDI.
  • To identify patient subgroups who benefit most from bezlotoxumab treatment.

Main Methods:

  • Two large, randomized, double-blind, placebo-controlled trials were conducted.
  • Adult patients at increased risk for CDI recurrence received intravenous bezlotoxumab (10 mg/kg) or placebo as adjunctive therapy.

Related Experiment Videos

  • Efficacy was assessed by the rate of recurrent CDI; safety, including adverse events, was monitored.

    • Main Results:

    • Bezlotoxumab significantly reduced the risk of recurrent CDI compared to placebo in high-risk adult patients.
    • Patients aged over 65, with a history of CDI, immunocompromised status, or severe CDI showed significant benefit.
    • Bezlotoxumab was generally well-tolerated, but an increased risk of heart failure was observed in patients with pre-existing congestive heart failure.

    Conclusions:

    • Bezlotoxumab is an effective adjunctive therapy for preventing recurrent CDI in at-risk adult populations.
    • Risk stratification identifies patients most likely to benefit from bezlotoxumab.
    • Further research is needed to optimize bezlotoxumab use and manage potential cardiac risks.